

(10) International Publication Number
WO 2016/049000 A2(43) International Publication Date
31 March 2016 (31.03.2016)(51) International Patent Classification:
C07K 16/24 (2006.01)(21) International Application Number:
PCT/US2015/051407(22) International Filing Date:
22 September 2015 (22.09.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/054,167 23 September 2014 (23.09.2014) US(71) Applicant: REGENERON PHARMACEUTICALS,
INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown,
New York 10591-6707 (US).(72) Inventors: ORENGO, Jamie M.; c/o Regeneron Pharma-
ceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown,
New York 10591 (US). ALLINNE, Jeanne; c/o Regener-
on Pharmaceuticals, Inc., 777 Old Saw Mill River Road,
Tarrytown, New York 10591 (US).(74) Agents: CROWLEY-WEBER, Cara L. et al.; Brown-
stein Hyatt Farber Schreck, LLP, 410 Seventeenth Street,
Suite 2200, Denver, Colorado 80202 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

[Continued on next page]

(54) Title: ANTI-IL-25 ANTIBODIES AND USES THEREOF

Binding of mAb-2 to IL-25 which is Pre-Complexed with mAb-1																		
mAb-1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
1	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
2	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
3	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
4	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
5	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
6	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
7	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
8	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
9	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
10	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
11	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
12	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
13	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
14	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
15	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
16	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
17	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95
18	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95

FIGURE 1

(57) Abstract: The present invention provides anti-
bodies that bind to human interleukin-25 (IL-25)
and methods of using the same. According to cer-
tain embodiments, the antibodies of the invention
bind human IL-25 with high affinity. In certain
embodiments, the invention includes antibodies
that bind human IL-25 and block IL-25-mediated
cell signaling. The antibodies of the invention may
be fully human, non-naturally occurring antibod-
ies. The antibodies of the invention are useful for
the treatment of various disorders associated with
IL-25 activity or expression, including asthma, al-
lergy, chronic obstructive pulmonary disease
(COPD), inflammatory bowel disease (IBD), in-
cluding ulcerative colitis and Crohn's disease,
atopic dermatitis (AD), and Eosinophilic Granulo-
matosis with Polyangiitis (EGPA), also known as
Churg-Strauss Syndrome.

— *with sequence listing part of description (Rule 5.2(a))*